| A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of a Hydrolyzed Chicken Collagen Type II Supplement in Alleviating Joint Discomfort 2021 · AVC-H2 group · Men and women aged 40–65 in good general health with joint pain, stiffness, or other joint-related discomfort | 2.5 g | 8 weeks | 47 |
| Randomized, double-blind, four-arm pilot study on the effects of chicken essence and type II collagen hydrolysate on joint, bone, and muscle functions 2023 · HC-II · Adults aged 45–75 with mild to moderate knee osteoarthritis and knee pain | 2 g | 24 weeks | 38 |
| Randomized, double-blind, four-arm pilot study on the effects of chicken essence and type II collagen hydrolysate on joint, bone, and muscle functions 2023 · EC-HC-II · Adults aged 45–75 with mild to moderate knee osteoarthritis and knee pain | 2 g | 24 weeks | 37 |
| A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis 2009 · CCII group · Adults aged 18–65 with rheumatoid arthritis of 6–24 months’ duration and active disease | 100 mcg | 24 weeks | 326 |
| Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study 2016 · UC-II group · Men and women aged 40–75 with moderate-to-severe knee osteoarthritis | 20 mg | 180 days | 63 |
| UC-II Undenatured Type II Collagen for Knee Joint Flexibility: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study 2022 · undenatured collagen group · Healthy males and females aged 20–55 with activity-related knee-joint discomfort during or after physical activity | 40 mg | 24 weeks | 48 |
| Efficacy and Safety of Dietary Undenatured Type II Collagen on Joint and Motor Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study 2023 · NEXT-II group · Healthy Japanese male and female participants aged 20 years and older | 3.2 mg | 12 weeks | 30 |
| Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial 1996 · 1 mg/day type II collagen group · Patients with early rheumatoid arthritis (disease duration ≤3 years) | 1 mg | 12 weeks | 30 |
| Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial 1996 · 10 mg/day type II collagen group · Patients with early rheumatoid arthritis (disease duration ≤3 years) | 10 mg | 12 weeks | 30 |
| Control of rheumatoid arthritis by oral tolerance 2001 · 0.05 mg CII group · Adults with active rheumatoid arthritis for at least 2 years who had failed treatment with at least one slow-acting drug | 50 mcg | 26 weeks | — |
| Control of rheumatoid arthritis by oral tolerance 2001 · 0.5 mg CII group · Adults with active rheumatoid arthritis for at least 2 years who had failed treatment with at least one slow-acting drug | 500 mcg | 26 weeks | — |
| Control of rheumatoid arthritis by oral tolerance 2001 · 5 mg CII group · Adults with active rheumatoid arthritis for at least 2 years who had failed treatment with at least one slow-acting drug | 5 mg | 26 weeks | — |
| A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid arthritis 2008 · CCII group · Patients with active rheumatoid arthritis | 100 mcg | 24 weeks | — |
| Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial 1998 · 20 microg/day CII · Patients with active rheumatoid arthritis | 20 mcg | 24 weeks | — |
| Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial 1998 · 100 microg/day CII · Patients with active rheumatoid arthritis | 100 mcg | 24 weeks | — |
| Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial 1998 · 500 microg/day CII · Patients with active rheumatoid arthritis | 500 mcg | 24 weeks | — |
| Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial 1998 · 2,500 microg/day CII · Patients with active rheumatoid arthritis | 2.5 mg | 24 weeks | — |
| Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial 2009 · UC-II group · Adults with moderate to severe osteoarthritis of the knee; age and sex distribution not specified for this arm. | 50 mg | 90 days | 26 |
| Novel Hydrolyzed Chicken Sternal Cartilage Extract Improves Facial Epidermis and Connective Tissue in Healthy Adult Females: A Randomized, Double-Blind, Placebo-Controlled Trial 2019 · intervention · Females aged 39–59 years described as healthy adults | 600 mg | 12 weeks | — |
| Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study 2015 · GCQID group · Japanese women and men aged 40–74 years with knee pain | 45 mg | 16 weeks | 50 |
| Effects of cartilage-supporting nutritional supplementation on knee osteoarthritis symptoms and quality of life in a 12-week randomized double-blind placebo-controlled pilot study 2025 · Verum · Adults with mild-to-moderate knee osteoarthritis and slight-to-moderate knee pain; mean age 62.7 years; women and men | 60 mg | 12 weeks | 36 |
| A Dietary Supplement in the Management of Patients with Lumbar Osteochondrosis: A Randomized, Double-Blinded, Placebo-Controlled Study 2024 · supplement group · Adults with symptomatic MRI-confirmed lumbar osteochondrosis; age range and sex not specified | 360 mg | 90 days | 26 |
| Effect of supplementation with type 1 and type 3 collagen peptide and type 2 hydrolyzed collagen on osteoarthritis-related pain, quality of life, and physical function: A double-blind, randomized, placebo-controlled study 2025 · Collagen · Adults aged 35–65 with unilateral Kellgren-Lawrence grade 2–3 knee osteoarthritis | 40 mg | 8 weeks | 16 |
| The effect of supplementation with type I and type III collagen peptide and type II hydrolyzed collagen on pain, quality of life and physical function in patients with meniscopathy: a randomized, double-blind, placebo-controlled study 2025 · collagen group · men and women aged 35–65 with grade 1 or 2 meniscal tears | 40 mg | 8 weeks | 17 |